Yong W. Moon
Songnam, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 08, 2026
OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 26, 2025
JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.
Journal: British journal of cancer
Published: June 01, 2025
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer.
Journal: International journal of molecular sciences
Published: September 21, 2024
SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer.
Journal: Cell death & disease
Published: September 10, 2024
PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.
Journal: International journal of molecular sciences
Published: November 16, 2023
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer.
Journal: Cancers
Published: August 27, 2023
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: August 24, 2023
Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors.
Journal: Anticancer research
Published: October 25, 2022
: A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: Review of literature.
Journal: Medicine
Published: September 10, 2022
Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies.
Journal: Cancer research and treatment
Published: August 23, 2022
Last Updated: 09/26/2026